


CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a subject with pancreatic cancer, comprising administering an effective amount of a compound of structural formula (I):




or a pharmaceutically acceptable salt thereof, wherein:

each R^a is independently -H or methyl;

R¹ is -H, or methoxy; and


R^2 is $-H$, or methyl.

2. The method of Claim 1, wherein the compound is represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

3. The method of Claim 1, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

4. The method of Claim 1, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

5. The method of Claims 1-4 wherein the pancreatic cancer is an exocrine tumor.
6. The method of Claims 1-4 wherein the pancreatic cancer is a neuroendocrine tumor.
7. The method of Claim 5, wherein the exocrine tumor is selected from the group consisting of acinar cell carcinoma, adenocarcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm (IPMN), mucinous cystadenocarcinoma, pancreatoblastoma, serous cystadenocarcinoma, and solid and pseudopapillary tumors.
8. The method of Claim 6, wherein the neuroendocrine tumor is selected from the group consisting of gastrinoma (Zollinger-Ellison Syndrome), glucagonoma, insulinoma,


nonfunctional islet cell tumor, somatostatinoma, and vasoactive intestinal peptide-releasing tumor (VIPoma or Verner-Morrison Syndrome).

9. The method of Claims 1-4, wherein the pancreatic cancer is adenocarcinoma.
10. The method of Claims 1-9, wherein the pancreatic cancer is hypoxic.
11. The method of Claims 1-9, wherein the pancreatic cancer is non-hypoxic.
12. The method of any one of Claims 1-11, further comprising co-administering an additional therapeutic agent.
13. The method of Claim 12, wherein the additional therapeutic agent is an anti-cancer drug.
14. The method of Claim 13, wherein the anti-cancer drug is Gemcitabine.
15. The method of Claim 13, wherein the anti-cancer drug is Cisplatin.

CLAIMS

WHAT IS CLAIMED IS:


1. Use of a compound of structural formula (I):



(I),


or a pharmaceutically acceptable salt thereof, wherein: each R^a is independently -H or methyl; R¹ is -H, or methoxy; and R² is -H, or methyl, in the manufacture of a medicament for treating a subject with pancreatic cancer.

2. The use of claim 1, wherein the compound is represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

5. The use of claims 1-4, wherein the pancreatic cancer is an exocrine tumor.
6. The use of claims 1-4, wherein the pancreatic cancer is a neuroendocrine tumor.
7. The use of claim 5, wherein the exocrine tumor is selected from the group consisting of acinar cell carcinoma, adenocarcinoma, adenosquamous carcinoma, giant cell tumor, intraductal papillary-mucinous neoplasm (IPMN), mucinous cystadenocarcinoma, pancreatoblastoma, serous cystadenocarcinoma, and solid and pseudopapillary tumors.
8. The use of Claim 6, wherein the neuroendocrine tumor is selected from the group consisting of gastrinoma (Zollinger-Ellison Syndrome), glucagonoma, insulinoma, nonfunctional islet cell tumor, somatostatinoma, and vasoactive intestinal peptide-releasing tumor (VIPoma or Verner-Morrison Syndrome).
9. The use of Claims 1-4, wherein the pancreatic cancer is adenocarcinoma.

10. The use of Claims 1-9, wherein the pancreatic cancer is hypoxic.
11. The use of Claims 1-9, wherein the pancreatic cancer is non-hypoxic.
12. The use of any one of claims 1-11, wherein the medicament is adapted to be co-administrable with an additional therapeutic agent.
13. The use of claim 12, wherein the additional therapeutic agent is an anti-cancer drug.
14. The use of claim 13, wherein the anti-cancer drug is Gemcitabine.
15. The use of claim 13, wherein the anti-cancer drug is Cisplatin.